April 2009 Volume 9 Number 4
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=23&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cancer online. To purchase a subscription,
please visit: http://links.ealert.nature.com/ctt?kn=24&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=36&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cancer Impact Factor: 29.19 *
(*Journal Citation Reports, Thomson, 2007)
*********************************************************************
=========================== ADVERTISEMENT ===========================
This alert is sponsored by Agilent technologies
Why not take a multifaceted look at your cancer genome?
Agilent offers a single microarray platform for CGH, miRNA, gene expression,
and DNA methylation, giving you a more complete view of the disease. So
why not use a research platform capable of meeting the complexity of cancer
itself, with DNA microarrays from Agilent. Learn more at
http://links.ealert.nature.com/ctt?kn=9&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Programming antibodies to treat cancer and autoimmune diseases.
http://links.ealert.nature.com/ctt?kn=81&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Scripps researchers have devised a means of inducing antibodies by vaccine
and then programming them with a target-specific molecule in vivo to treat
mouse models of cancer. Programmed antibodies could also be used to treat
autoimmune diseases, although it is not yet clear that they could treat
infectious diseases. How does this approach change the landscape for
conventional vaccine or infused antibody therapies?
Find out more by reading the first in-depth analysis of the scientific and
commercial potential of the work in SciBX: Science-Business eXchange.
http://links.ealert.nature.com/ctt?kn=86&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
This month's Special feature:
Focus: Migration and metastasis
http://links.ealert.nature.com/ctt?kn=98&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=====================================================================
From the editors
p225 | doi:10.1038/nrc2638
http://links.ealert.nature.com/ctt?kn=90&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Metastasis: Oxidizing abnormalities
p227 | doi:10.1038/nrc2624
http://links.ealert.nature.com/ctt?kn=58&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metastasis: When good drugs do bad things
p228 | doi:10.1038/nrc2632
http://links.ealert.nature.com/ctt?kn=47&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Insertional Mutagenesis: Flip'in beautiful
p228 | doi:10.1038/nrc2634
http://links.ealert.nature.com/ctt?kn=41&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metabolism: Monitoring progression
p229 | doi:10.1038/nrc2630
http://links.ealert.nature.com/ctt?kn=8&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Migration: Calcium influx is moving
p230 | doi:10.1038/nrc2629
http://links.ealert.nature.com/ctt?kn=67&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Resistance: Aggravating the aggressor
p230 | doi:10.1038/nrc2633
http://links.ealert.nature.com/ctt?kn=39&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
IN THE NEWS
Cancer-free iPS
p230 | doi:10.1038/nrc2636
http://links.ealert.nature.com/ctt?kn=33&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
IN BRIEF
Metabolism | Therapeutics
p231 | doi:10.1038/nrc2637
http://links.ealert.nature.com/ctt?kn=73&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metastasis: CHIPping away at tumour progression
p232 | doi:10.1038/nrc2623
http://links.ealert.nature.com/ctt?kn=88&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metastasis: Suppression by Snail
p232 | doi:10.1038/nrc2631
http://links.ealert.nature.com/ctt?kn=20&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
TRIAL WATCH
Metabolic mutations in gliomas
p232 | doi:10.1038/nrc2635
http://links.ealert.nature.com/ctt?kn=37&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metastasis: A malignant mutation
p233 | doi:10.1038/nrc2625
http://links.ealert.nature.com/ctt?kn=50&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
----------------------
FOREWORD
----------------------
Charting a course to a distant site
Mary J. C. Hendrix
p237 | doi:10.1038/nrc2626
Abstract: http://links.ealert.nature.com/ctt?kn=18&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=31&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=====================================================================
Focus on: Migration and metastasis
http://links.ealert.nature.com/ctt?kn=98&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Microenvironmental regulation of metastasis
Johanna A. Joyce and Jeffrey W. Pollard
p239 | doi:10.1038/nrc2618
Metastatic dissemination and growth at distant sites are influenced by
cells of the tumour microenvironment. What roles do these cells have
in the underlying processes that determine metastatic growth?
Abstract: http://links.ealert.nature.com/ctt?kn=102&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=95&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Learning therapeutic lessons from metastasis suppressor proteins
Steven Christopher Smith and Dan Theodorescu
p253 | doi:10.1038/nrc2594
Metastasis suppressors inhibit metastasis but not the development of a
primary tumour. Many of these genes have now been identified, and the
therapeutic potential of restoring metastasis suppressor function is
beginning to be examined.
Abstract: http://links.ealert.nature.com/ctt?kn=87&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=72&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Transitions between epithelial and mesenchymal states: acquisition of
malignant and stem cell traits
Kornelia Polyak and Robert A. Weinberg
p265 | doi:10.1038/nrc2620
Transitions between epithelial and mesenchymal states seem to promote
tumour heterogeneity and metastasis. This Review discusses the connections
between epithelial and mesenchymal transitions and the acquisition of stem
cell-like phenotypes.
Abstract: http://links.ealert.nature.com/ctt?kn=40&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=70&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Metastasis: from dissemination to organ-specific colonization
Don X. Nguyen, Paula D. Bos and Joan Massague
p274 | doi:10.1038/nrc2622
The natural history of metastasis - which appears to be cancer-type
specific - varies by target organ, latency and severity. This Review
discusses how organ speciation and the competence to colonize might
develop.
Abstract: http://links.ealert.nature.com/ctt?kn=92&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=51&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
The metastatic niche: adapting the foreign soil
Bethan Psaila and David Lyden
p285 | doi:10.1038/nrc2621
How are sites of metastases chosen? Accumulating evidence suggests that
primary tumour cells and circulating tumour cells might facilitate changes
to the microenvironment in target organs so that a pre-metastatic niche,
ideal for engraftment, forms.
Abstract: http://links.ealert.nature.com/ctt?kn=10&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=56&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
OPINION
MicroRNAs - the micro steering wheel of tumour metastases
Milena S. Nicoloso, Riccardo Spizzo, Masayoshi Shimizu, Simona Rossi
and George A. Calin
p293 | doi:10.1038/nrc2619
microRNAs have recently been shown to affect diverse processes involved
in metastasis. How do microRNAs interfere with or promote metastasis,
could they be used as predictive markers, and are they possible therapeutic
targets?
Abstract: http://links.ealert.nature.com/ctt?kn=42&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=27&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
OPINION
Parallel progression of primary tumours and metastases
Christoph A. Klein
p302 | doi:10.1038/nrc2627
When, in tumour progression, might metastasis be initiated? This Perspective
argues that tumour cells disseminate early in malignant progression of the
primary tumour so that disseminated tumour cells evolve the traits to allow
growth within the metastatic site independently from the primary tumour.
Abstract: http://links.ealert.nature.com/ctt?kn=53&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=59&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Nature Clinical Practice Oncology is now Nature Reviews Clinical Oncology.
Nature Reviews Clinical Oncology brings the distinguished reputation of
the Nature Reviews series into the clinical sciences. The journal will
remain dedicated to publishing the latest advances in oncology.
For more information visit http://links.ealert.nature.com/ctt?kn=7&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=19&m=32177098&r=MTc2Njc4NzkyNgS2&b=2&j=NDY4MzcwOTkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
